Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1652

Current Trends in Gastroenterology and Hepatology

Mini Review(ISSN: 2641-1652)

Potassium-Competitive Acid Blocker: Novel Class of Anti- Acid Drug

Volume 2 - Issue 2

Jaeyong Han MD1,2, Seung Hun Lee MD3 and Tong Wang MD1*

  • Author Information Open or Close
    • 1 Department of Cellular and Molecular Physiology, Yale University, New Haven, CT, USA
    • 2 Department of Internal Medicine, Seoul Bon Clinic, Seoul, Korea
    • 3 Department of Internal Medicine, Section of Nephrology, New Haven, USA

    *Corresponding author: Tong Wang, Department of Cellular and Molecular Physiology, New Haven, USA

Received:March 09, 2019;   Published: March 14, 2019

DOI: 10.32474/CTGH.2018.01.000131

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Over the past several decades, great progress has been made on understanding mechanisms of gastric acid secretion for developing new anti-acid drugs. Until now most commonly used anti-acid drugs are histamine-2 receptor antagonists and proton pump inhibitors (PPIs) for patients to control acid related disease. However, several clinical limitations of these drugs had been reported. Recently, a new generation of potassium-competitive acid blockers (P-CABs) were launched for clinical use. It has been shown that these new drugs are more convenient and powerful to treat gastric acid-related diseases. In this article, we briefly reviewed the clinical use of this new anti-acid drug P-CAB.

Keywords:Potassium-competitive Acid Blocker; Potassium channel; H+/K+-ATPase

Abstract| Introduction| Discussion| Conclusion| References|